|
|
Your Rexy Weekly Digest
Smart Evidence. Delivered.
|
|
What changed
New guidance and approvals in your specialty
|
|
Broader Pick
1. In Obesity Treatment, Physical Activity's Benefits Go Beyond Weight Loss, Says AHA.
Anderer et al., JAMA, July 2026
This is a consensus statement synthesizing existing evidence on physical activity in obesity care, not a single original study.
The American Heart Association's new scientific statement emphasizes that physical activity in obesity treatment provides health benefits that extend well beyond weight loss alone—including cardiovascular and metabolic improvements independent of body weight change.
|
Why it matters
Clinicians often frame exercise to obese patients primarily as a weight-loss tool, which can discourage adherence when the scale doesn't move. This statement argues that physical activity should be prescribed for its direct health gains (heart health, blood sugar control, fitness) even in the absence of significant weight reduction—a potentially more motivating message that aligns with what the evidence actually shows.
|
👎 tells Rexy this one missed — the paper is shown
to the editor that picks your next digest, as an example of what
you do not want.
|
|
|
Broader Pick
2. Safely Supporting the Establishment of Breastfeeding in the Setting of Fentanyl Use Before the Birth Hospitalization.
Ostfeld-Johns et al., Obstetrics and gynecology, September 2026
This is a clinical consensus synthesis building on the 2023 Academy of Breastfeeding Medicine protocol, drawing on available pharmacokinetic data, breast-milk transmission literature, and clinical experience rather than new empirical data.
The authors propose a harm-reduction clinical approach for breastfeeding initiation in mothers with recent nonprescribed fentanyl use: wait 72 hours after the most recent use, then begin breastfeeding when paired with parental treatment engagement, newborn monitoring, and hospital-based multidisciplinary support. The guidance includes contingency planning (cessation protocols, alternate caregiver identification, and formula backup) if return to substance use occurs.
|
Why it matters
This is the first structured clinical guidance addressing a common real-world scenario—mothers actively using nonprescribed fentanyl who want to breastfeed—where prior evidence was sparse. It moves beyond a blanket recommendation against breastfeeding and instead offers clinicians a practical, stigma-reducing framework to support safe feeding while maintaining harm reduction and newborn safety.
|
👎 tells Rexy this one missed — the paper is shown
to the editor that picks your next digest, as an example of what
you do not want.
|
|
|
For you
Matched to the interests you told us about
|
|
| Original Research |
moderate evidence
|
3. Initiation of Medications for Alcohol Use Disorder Among Hospitalized Veterans : A Retrospective Cohort Study.
Anderson et al., Annals of internal medicine, June 2026
Retrospective cohort study of hospitalized veterans in the VA system; findings are limited to VA settings and may not generalize to community or non-VA hospitals.
Among nearly 30,000 hospitalizations for alcohol use disorder across 142 VA hospitals, only 30.8% of veterans received a medication for alcohol use disorder (naltrexone, acamprosate, or injectable naltrexone) either as an inpatient or within 7 days of discharge. Initiation rates varied substantially between hospitals (median 29.9%, range 22.6%–36.3%). Certain patient groups—those aged 65+, men, American Indian/Alaska Native veterans, frail veterans, those with opioid use disorder, and ICU patients—were significantly less likely to receive these medications.
|
Why it matters
Hospitalization for alcohol use disorder is a high-leverage moment to start proven medications that reduce relapse and improve outcomes, yet nearly 70% of eligible patients are discharged without receiving them. The wide variation between hospitals suggests that implementation gaps—not patient factors alone—are driving underuse, and identifying successful hospital strategies could substantially improve treatment uptake.
|
👎 tells Rexy this one missed — the paper is shown
to the editor that picks your next digest, as an example of what
you do not want.
abstract only
|
|
|
| Original Research |
moderate evidence
|
4. Collaborative care intervention for risky opioid use among primary care patients: The STOP randomized clinical trial.
McNeely et al., Addiction, June 2026
Cluster-randomized trial across 5 U.S. sites with 202 patients (mostly white, female, mean age 56) who had risky opioid use but not yet moderate-severe OUD; moderate attrition by 6 months (87.5% STOP, 93.9% EUC completion).
A collaborative care intervention (brief PCP advice, embedded nurse care manager, and health coaching) did not reduce days of risky opioid use over 6 months compared to enhanced usual care (12.2 vs 15.5 days; difference not statistically significant). However, fewer intervention participants developed moderate-severe opioid use disorder by 6 months (1.1% vs 11.4%, p<0.001).
|
Why it matters
This is the first randomized trial of a preventive intervention in primary care for at-risk opioid users who haven't yet developed full OUD. While the intervention didn't reduce overall opioid use days, the large reduction in progression to severe OUD suggests potential value—but the finding was secondary and the primary outcome was negative, so the evidence for routine adoption is not yet convincing. High baseline pain burden in both groups hints that addressing pain management itself may be necessary.
|
👎 tells Rexy this one missed — the paper is shown
to the editor that picks your next digest, as an example of what
you do not want.
abstract only
|
|
|
| Original Research |
weak evidence
|
5. Seeding research at the coal face: evaluation of an australian regional primary care capacity building initiative.
Withanage et al., BJGP open, September 2026
Evaluation of a single regional initiative in outer Eastern Melbourne using interviews with 29 stakeholders; findings reflect implementation in one geographic area with established partnerships rather than a controlled comparison.
A regional primary care research capacity-building program (TROPHI) increased clinician research skills and confidence, generated early evidence translation into practice, and leveraged an initial AUD$1M investment into more than AUD$3M in competitive grants over three years through mentorship, bursaries, fellowships, and seed funding.
|
Why it matters
If you work in primary care and feel isolated from research or lack pathways to contribute, this shows that structured mentorship and seed funding can build skills and translate evidence into practice at the regional level. It's a proof-of-concept that capacity building models can work, though scaling and sustainability remain open questions.
|
👎 tells Rexy this one missed — the paper is shown
to the editor that picks your next digest, as an example of what
you do not want.
abstract only
|
|
|